Bonding Time In China: Multinationals Tap Closer R&D Ties With Domestics
This article was originally published in PharmAsia News
Executive Summary
As the Chinese government becomes more assertive in regulatory and enforcement activity, Big Pharma like Eli Lilly are turning to partnerships with local companies to foster closer ties with stakeholders, get policy support and accelerate R&D via green channels.